Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma
Status unconfirmed · Phase 2
Conditions studied: Epithelial Ovarian Carcinoma
In brief
Initially, the prospect of metformin as a neoplastic treatment was considered for malignancies of the prostate, colon and pancreas. However, only select clinical studies involving the use of metformin in the treatment of ovarian cancer have documented improved survival rates. Since no first line regimen has demonstrated compelling superiority in the management of advanced stage ovarian carcinoma, the combination of paclitaxel, carboplatin, and metformin is of particular interest given the triplet's prospect for achieving increased synergy without compromising patient tolerability.
Key facts
- Study ID
- NCT02437812
- Run by
- Gynecologic Oncology Associates
- People needed
- 30
- Starts
- 2014-01-01
- Expected to finish
- 2021-04-01
- Last updated by the study team
- 2017-02-28
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Female Gender
- Age greater than 18 years
- Advanced stage epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Adequate bone marrow function
- ECOG performance score of 2 or greater
- Patients must be able to swallow oral medication.
You may not qualify if…
- Subjects must NOT be taking metformin or have been on metformin in the past 6 months.
- Subjects with a diagnosis of epithelial ovarian, fallopian tube or peritoneal cancers of low malignant potential (borderline carcinomas)
- Subjects with concomitant malignancy or a previous malignancy within the past three years, melanoma skin cancer excepted
Where it is running
- Gynecologic Oncology Associates — Newport Beach, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.